Safety and Efficacy of Insulin Degludec/Insulin Aspart in Patients With T2DM

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
In this multicenter, randomized, open-label, parallel-controlled, non-inferiority clinical trial, the efficacy and safety of insulin degludec/insulin aspart (IDegAsp) twice daily will be compared with degludec/insulin aspart (IDegAsp) once daily plus insulin aspart (IAsp) twice daily after 16weeks of treatment in patients with type 2 diabetes mellitus. This trial will enable primary assessment of the clinically relevant endpoint of a change in HbA1c.
Epistemonikos ID: 13fa57e47fb4e34b8a4ba79b4b045aecb27241ed
First added on: May 13, 2024